These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24205533)

  • 1. Types of blood cancers--and new molecular diagnostics.
    Dash DP; Janasik M
    MLO Med Lab Obs; 2013 Aug; 45(8):8, 10, 12. PubMed ID: 24205533
    [No Abstract]   [Full Text] [Related]  

  • 2. The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis.
    Anastasi J
    Hematol Oncol Clin North Am; 2009 Aug; 23(4):693-708. PubMed ID: 19577165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders.
    Bench AJ; Erber WN; Scott MA
    Clin Lab Haematol; 2005 Jun; 27(3):148-71. PubMed ID: 15938721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical myeloproliferative disorders in adults.
    Zachée P
    Transfus Apher Sci; 2011 Apr; 44(2):211-21. PubMed ID: 21402312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version.
    Iurlo A; Gianelli U; Cattaneo D; Thiele J; Orazi A
    Am J Hematol; 2017 Apr; 92(4):E48-E51. PubMed ID: 28109016
    [No Abstract]   [Full Text] [Related]  

  • 6. Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS.
    Alberti MO; Srivatsan SN; Shao J; McNulty SN; Chang GS; Miller CA; Dunlap JB; Yang F; Press RD; Gao Q; Ding L; Heusel JW; Duncavage EJ; Walter MJ
    Leukemia; 2018 Aug; 32(8):1874-1878. PubMed ID: 29959414
    [No Abstract]   [Full Text] [Related]  

  • 7. Establishing specific response criteria for MDS/MPN - Getting closer to reality?
    Villaume MT; Savona MR
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101170. PubMed ID: 32460975
    [No Abstract]   [Full Text] [Related]  

  • 8. Issue Highlights - July 2019.
    Cytometry B Clin Cytom; 2019 Jul; 96(4):253-255. PubMed ID: 31321907
    [No Abstract]   [Full Text] [Related]  

  • 9. Preface.
    Verstovsek S
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):81-2. PubMed ID: 25189719
    [No Abstract]   [Full Text] [Related]  

  • 10. Myeloid disease.
    Tallman MS
    Curr Opin Hematol; 2009 Mar; 16(2):63. PubMed ID: 19468265
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical applications of molecular haematology: an overview.
    Bain BJ
    J Assoc Physicians India; 2007 Jul; 55():503-6. PubMed ID: 17907501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic interface between histology and molecular tests in myeloproliferative disorders.
    Tefferi A; Vardiman JW
    Curr Opin Hematol; 2007 Mar; 14(2):115-22. PubMed ID: 17255788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative.
    Loscocco GG; Mannelli F; Guglielmelli P; Paoli C; Marone I; Cucci R; Coltro G; Sordi B; Albano F; Breccia M; De Stefano V; Finazzi G; Iurlo A; Martino B; Palandri F; Passamonti F; Siragusa S; Mannelli L; Fantoni D; Fazi P; Amadori S; Vignetti M; Barbui T; Vannucchi AM
    Am J Hematol; 2019 Sep; 94(9):E239-E242. PubMed ID: 31179561
    [No Abstract]   [Full Text] [Related]  

  • 14. [Changes of the WHO classification of myeloid neoplasms in the context of the 2016 revision].
    Marcinek J; Balhárek T; Plank L
    Cesk Patol; 2017; 53(3):118-121. PubMed ID: 28937778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Towards better understanding of hematolymphoid malignancies--based on the WHO-2008 classification: summary].
    Tohyama K
    Rinsho Byori; 2011 May; 59(5):502-3. PubMed ID: 21706866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical applications of molecular genetic testing in hematologic malignancies: advantages and limitations.
    Bagg A
    Hum Pathol; 2003 Apr; 34(4):352-8. PubMed ID: 12733115
    [No Abstract]   [Full Text] [Related]  

  • 17. [Optimising therapy in patients with haematological malignancies].
    Dumontet C
    Bull Cancer; 2008 Oct; 95(10):959-62. PubMed ID: 19004726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chromosomal analysis, fluorescence in situ hybridization method, and spectral karyotyping in hematologic malignancies].
    Nara N
    Rinsho Byori; 2003 Jun; Suppl 126():124-30. PubMed ID: 12905952
    [No Abstract]   [Full Text] [Related]  

  • 19. Pitfalls in molecular diagnosis in haemato-oncology.
    Mason J; Akiki S; Griffiths MJ
    J Clin Pathol; 2011 Apr; 64(4):275-8. PubMed ID: 21421696
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular diagnosis of hematopoietic neoplasms.
    Ramchandren R; Jazaerly T; Gabali AM
    Clin Lab Med; 2013 Dec; 33(4):817-33. PubMed ID: 24267188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.